Allergy Therapeutics CFO Shaun Furlong and Head of Late Stage Project Delivery Alan Bullimore talked at the Proactive One2One Investor forum about the company's focus on immunotherapy treatments designed to address the root causes of allergies rather than just managing symptoms.
Furlong outlined Allergy Therapeutics’ operations, highlighting that it achieved revenues of approximately £55 million last year and maintains a strong presence across Europe, especially in Germany and Spain. He said, “We see significant opportunity in our pipeline,” referring to two key products in development: the Grass MATA MPL immunotherapy, which has completed Phase III trials and is awaiting marketing authorization in Germany, and the VLP peanut allergy vaccine progressing through Phase I/II trials.
Bullimore explained how the company’s proprietary technologies, such as the MPL adjuvant and microcrystalline tyrosine depot, enable shorter treatment courses compared to traditional allergen immunotherapy. He also noted that Allergy Therapeutics is preparing for US market entry, with discussions planned with the FDA and expectations that the Grass MATA MPL product could meet a large unmet need.
The presentation also covered the potential expansion of the VLP platform to address other severe allergies, including additional nuts and environmental allergens. Furlong concluded by stating that the company has a clear path to the US market, a committed shareholder base, and an experienced leadership team.
#AllergyTherapeutics #Immunotherapy #BiotechInvesting #PeanutAllergy #GrassAllergy #VaccineDevelopment #FDAApproval #BiotechStocks #ClinicalTrials #HealthInnovation
